The percentage of patients with Metabolic Syndrome meeting National Cholesterol Education Program Adult Treatment Panel III (ATP III) LDL-C goals, using the patients included in the MERCURY I trial, according to treatment with rosuvastatin, atorvastatin, simvastatin, or pravastatin are displayed on the current slide.

At 8 weeks, the percentages of patients with Metabolic Syndrome who reached ATP III LDL-C goals was greater in the rosuvastatin 10mg group than in the atorvastatin 10mg, simvastatin 20mg or pravastatin 40mg groups.1

Reference:

1. Stender S. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes, Obesity and Metabolism. 2005;7:430–438.